Abstract Body

Background: Host genetic factors play an important role in disease. Due to its extensive role in the immune system, vitamin D may have a potential role in altering HIV disease progression. Vitamin D actions are mediated by the vitamin D receptor (VDR). Polymorphic variations exist in the VDR gene, each of which may have different significance in disease susceptibility and progression. We set out to examine if VDR gene variations, corresponding to Apa1, Bsm1, Fok1 and Taq1 polymorphisms were associated with HIV disease progression. Methodology: We analyzed cohort data for 142 HIV-infected patients initiating ART in South Africa between November 2008-March 2009. We defined disease progression as: 1) failure to achieve viral suppression (viral load <50copies/ml) within the first 12-months of ART and; 2) mortality during followup. Genomic DNA was extracted from whole blood using standard methods and analysed for polymorphisms in the VDR gene. Cox proportional hazards models were used to estimate the association of genotype status (Hazard Ratios (HR) and 95%CI) with disease progression. Models were adjusted for age, gender, BMI, WHO stage, CD4 count, haemoglobin level, employment status and ART regimen. Results: The genotype frequencies were as follows: Apa1: AA=42.3%, Aa=50% and aa=7.8%; Bsm1: BB=3.5%, Bb=32.4% and bb=64.1%; Fok1: FF=69.7%, Ff=29.6% and ff=0.7%; and Taq1 genotype, TT=60.6%, Tt=33.8% and tt=5.6%. The genotype distributions were in Hardy-Weinberg equilibrium (p > 0.05). By 12 months post-ART initiation, 22.2% failed to achieve viral suppression and over a median follow-up of 40.4 months (IQR 13.3-41.7) and 12.7% died. Patients with non-bb Bsm1 genotypes (BB+Bb) had 3.1-fold increased risk of failure to achieve viral suppression, adjusted HR (aHR) 3.05, 95%CI 1.18-7.90, p=0.02 and 3.4-fold increased risk of mortality during follow-up, aHR 3.37, 95%CI 1.28-8.86, p=0.01, vs. the bb Bsm1 genotype. A similar trend was observed for the non-FF Fok1 (Ff+ff) vs. FF Fok1 genotype but estimates were not statistically significant: risk of failure to achieve viral suppression, aHR 2.25, 95%CI 0.83-6.07, p= 0.11 and of mortality, aHR 2.11, 95%CI 0.75-5.87, p=0.16. No association with risk of disease progression was observed with Apa1 and Taq1 genotypes. Conclusions: Some VDR gene polymorphisms seem to contribute to differential rates of disease progression among HIV infected patients initiating ART. Patients carrying non-bb genotypes (BB+Bb) of the Bsm1 polymorphism demonstrated 3.1-fold increased risk of failure to achieve viral suppression and also 3.4-fold increased risk of mortality during follow-up. Understanding this role of VDR genotypes among HIV-infected patients may offer new insights for developing therapeutic strategies to alter disease progression.